Cargando…

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia

Detalles Bibliográficos
Autor principal:	Conte, William L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305883/ https://www.ncbi.nlm.nih.gov/pubmed/32593144 http://dx.doi.org/10.1016/j.msard.2020.102315

Ejemplares similares

Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study
por: Conte, William L.
Publicado: (2021)

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
por: Lucchini, Matteo, et al.
Publicado: (2020)

Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
por: Thornton, Jeanine Rempe, et al.
Publicado: (2020)

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
por: Iannetta, Marco, et al.
Publicado: (2020)

Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab
por: Khayat-Khoei, Mahsa, et al.
Publicado: (2021)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
por: Weberpals, Janick, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 in people living with HIV
por: Yamamoto, Shinya, et al.
Publicado: (2021)

Ocrelizumab: SARS-CoV-2 pneumonia: 2 case reports
Publicado: (2020)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
por: Anichini, Gabriele, et al.
Publicado: (2021)

The presence of SARS-CoV2 antibodies in MS patients
por: Wallach, Asya I., et al.
Publicado: (2021)

Temporal antibody responses to SARS-CoV-2 in patients of coronavirus disease 2019
por: Huang, Min, et al.
Publicado: (2020)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine
por: Conway, Sarah, et al.
Publicado: (2023)

Ocrelizumab/rituximab: SARS-CoV-2 infection: 2 case reports
Publicado: (2021)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
por: Katz, J.D., et al.
Publicado: (2022)

Kinetics and seroprevalence of SARS-CoV-2 antibodies in children
por: Roarty, Cathal, et al.
Publicado: (2021)

Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients
por: Del Zompo, Fabio, et al.
Publicado: (2021)

Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection
por: Wang, Hao, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Nazemipour, Maryam, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Ghafari, Mahan, et al.
Publicado: (2021)

Immunoassays for anti-SARS-CoV-2 antibodies: recent insights
por: Van Elslande, Jan, et al.
Publicado: (2021)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
por: Frey, Sarah, et al.
Publicado: (2021)

Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
por: Bradley, Todd, et al.
Publicado: (2021)

Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2021)

Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients
por: Gavriilaki, Eleni, et al.
Publicado: (2022)

Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies
por: Bellinvia, Angelo, et al.
Publicado: (2022)

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
por: Gibson, Elena G, et al.
Publicado: (2021)

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Testing for responses to the wrong SARS-CoV-2 antigen?
por: Rosadas, Carolina, et al.
Publicado: (2020)

SARS-CoV-2 N-gene mutation leading to Xpert Xpress SARS-CoV-2 assay instability
por: Foster, Charles S.P., et al.
Publicado: (2022)

Persistent SARS-CoV-2 Infection in a Multiple Sclerosis Patient on Ocrelizumab: A Case Report
por: Ambadapoodi, Raghava S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r1ki5id9vf9dtgjsirsvvrl0k6